Kangmei Pharmaceuticals to play the advantages of technological innovation to create rapid growth of enterprises

Kangmei Pharmaceuticals to take advantage of its large-scale research center, review the situation, the introduction of the "Internet plus medicine" development model, and constantly increase investment in Chinese medicine research and development, not only make the company in the industry leading position, but also promote the spread of excellent traditional Chinese medicine culture.
According to The third quarter 2017 financial report of Kangmei Pharmaceutical Co., Ltd. ("Kangmei Pharmaceuticals"), the company's assets amounted to 65.337 billion yuan, operating income was 19.515 billion yuan, and net income was 3.143 billion yuan, or 0.64 percent per share. Compared with the beginning of the establishment, the company has been rapid development. What has led to the rapid growth of Comey Pharmaceuticals? Answer: "Technological innovation". Specific performance in the following aspects:the introduction of the Internet plus, keep pace with the times
at the macro level, in accordance with national policy requirements, in line with the development trend of the pharmaceutical industry. In accordance with the Outline of the Outline of the Chinese Medicine Development Strategy Plan (2016-2030), the Outline of the Plan for Healthy China 2030, the White Paper on Chinese Medicine in China, the Chinese Medicine Law, the Guide to the Development of the Pharmaceutical Industry Development Plan, and other legal policies, the Company has created a new model for the development of the Chinese medicine industry with "Kangmei characteristics".
at the mid-view level, the company actively embraces the Internet plus, with the Internet thinking, layout of the "big health, big platform, big data, big service" system, promoting the upgrading of the entire industrial chain of Chinese medicine. At the same time, the introduction of professional team to enhance cloud computing, information services, in the Internet and smart medical, medical information, cancer treatment management, intelligent old-age care, network hospitals and other fields to seek new breakthroughs and development, the formation of intelligent production and operation system.
At the micro level, the company pioneered the "smart pharmacy" of the new model of smart medicine, has been recognized by Beijing, Shanghai, Chengdu and other hospitals, and reached an agreement with the other side, and gradually built a central pharmacy in the city group, forming a new development model of Internet and medicine, for the company's development has brought a new opportunity. At the same time, the company self-built Chinese herbal medicine bulk trading market, forming the company in the Chinese herbal medicine physical trading market leading position and resource advantages.
In addition, the company also built a large trading platform for Chinese herbal medicine (Conme e-medicine valley) B2B e-commerce platform, the platform is the Ministry of Commerce's first batch of Chinese herbal medicine e-commerce demonstration platform, Kangmei e-drug valley since the online operation of a total of Shenzhen, Guangzhou Pan'an, Nanjing, Hangzhou, Xining, Wuhan and other 17 regional service centers, as well as covering the country's main pharmaceutical production areas a total of more than 380 secondary service outlets, expanding the company's product sales channels, for the company's further growth in operating income provides favorable conditions. In order to adapt to the operation and development of B2B commercial platform, the company has set up more than 30 modern pharmaceutical storage and logistics centers in Beijing, Northeast China, Shanghai, Puning, Sichuan, etc., to improve the service capacity and level of e-commerce.Large-scale research center, hardware support
Kangmei pharmaceutical business covers Chinese medicine tablets, Chinese herbal medicine trade, pharmaceutical production and sales, health care products and health food, Chinese medicine market operations, pharmaceutical e-commerce and medical services. In 2015 and 2016, sales revenue of Chinese medicine tablets was RMB3.720 billion and RMB4.704 billion, respectively, accounting for 20.59 percent and 21.73 percent of the current year's operating income, respectively, accounting for more than 1/5 of all operating income, indicating that Chinese medicine tablets in the company's income-generating position.
company has the domestic Chinese medicine tablets national joint local engineering research center, Chinese medicine tablets standard key research room, with Guangdong Province, Chinese medicine standardization technical committee, Guangdong Province Chinese medicine tablets engineering technology research and development center, Guangdong Province Chinese medicine tablets enterprise key laboratory, Guangdong Chinese medicine industry technology innovation alliance and other public services and technological innovation support platform; Built a national enterprise technology center, enterprise postdoctoral research workstation. These research and development centers provide the company with abundant research resources and hardware support for technological innovation. At present, the company can produce more than 1,000 kinds, more than 20,000 products, is one of the most competitive business sectors.sufficient investment in research and development, financial support
is an effective support for research and development activities, and research and development activities are an important condition for technological innovation. The company's research and development staff has increased from 537 in 2015 to 570 in 2016, with a small increase, injecting new resources into the company's research and development activities and helping to drive the research and development process.
In terms of investment in research and development funds, (see Table 1) from 2014 to 2016 year by year, research and development investment in 2016 than in 2014 more than twice the investment of more than 8 million yuan, enough to show that the company's emphasis on pharmaceutical research and development, but also released research and development is to promote the company's development.
Compared with the investment in research and development of similar companies in the same industry, (see table 2) Kangmei Pharmaceuticals ranked third, for the establishment of the remaining five companies (except Changsheng Bio), indicating that Kangmei Pharmaceuticals in the same industry in the importance of research and development is at a high level.
results stimulate
the company's research and development results on the one hand in research and development expenditure - capitalized expenditure increased, on the other hand, the increase in the number of invention patents. The Company's research and development expenditures for 2014-2016 - capitalized expenditures, expense expenditures, see Table 3 for details. As can be seen from the table, the proportion of capital expenditure of the company has increased in the past three years, and the research and development activities have been outstanding. And research and development activities, regardless of the results are the company's further research and development experience, to promote the process of research and development activities.
, on the other hand, according to the 2016 financial report, in 2016 the company newly authorized invention patents 13, 4 applications accepted; Through the acceptance of Guangdong Province science and technology projects 3; Two clinical approvals for chemical drugs were approved by the State Administration of Food and Drug Administration, one of which entered the preparatory stage of clinical trials; 1 health food Kangmei ® tea (approval number: G20160226); There are four newly declared chemical drugs reviewed by the Drug Approval Center of the State Food and Drug Administration. By the end of 2016, the company had nearly 300 invention patents, utility model patents, design patents and software copyrights.
addition, the company's enterprise technology center was recognized as the national enterprise technology center, Xin Kaihe, McKinley and other subsidiaries to obtain high-tech enterprises identified, the introduction of more than 100 large health products, fast health food.
, 2017 (Xinhua) -- Selected as the 2017 National Intellectual Property Demonstration Enterprise and Intellectual Property Advantage Enterprise.
In summary, Kangmei Pharmaceuticals took advantage of its large-scale research center, reviewed the situation, introduced the "Internet plus medicine" development model, and continuously increased investment in Chinese medicine research and development, not only to make the company in the industry leading position, but also to promote the spread of excellent traditional Chinese medicine culture. (China Visit.com)